Lifecore Biomedical, Inc. LFCR CDMO — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lifecore Biomedical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lifecore Biomedical, Inc.'s cdmo — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lifecore Biomedical, Inc.'s CDMO — revenue?
- Lifecore Biomedical, Inc. (LFCR) reported CDMO — revenue of $15.78M in Q1 2026.
- How has Lifecore Biomedical, Inc.'s CDMO — revenue changed year-over-year?
- Lifecore Biomedical, Inc.'s CDMO — revenue decreased by 32.9% year-over-year, from $23.52M to $15.78M.
- What does CDMO — revenue mean?
- This metric represents the total gross revenue generated from contract development and manufacturing services provided to pharmaceutical and biotechnology clients. It reflects the financial performance of the business unit responsible for the development, filling, and finishing of complex sterile injectable products. Growth in this segment indicates successful client acquisition and the effective scaling of specialized manufacturing capabilities.